Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 6Unknown 4Recruiting 2Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 5Stomach Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Neoplasms 2Melanoma 2Advanced Pancreatic Cancer 2Thoracic Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Lung 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Second Line Treatment of Gastric Cancer 1Sarcoma 1Resectable Biliary Tract Cancer 1Pathologic Complete Response 1Pancreatic Adenocarcinoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-Invasive Bladder Carcinoma 1Lung Diseases 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Cisplatin 32Paclitaxel 29Radiotherapy 21Fluorouracil 20Radiation 12camrelizumab 11Oxaliplatin 11Docetaxel 11Carboplatin 10Capecitabine 9Esophagectomy 8Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 6Leucovorin 6Endoscopic Mucosal Resection 6Drug Therapy 6apatinib 5Neoadjuvant Therapy 5Chemoradiotherapy 5nedaplatin 4S 1 (combination) 4Preoperative Exercise 4Irinotecan 4Endoscopy 4Cetuximab 4Albumin-Bound Paclitaxel 4pembrolizumab 3TP protocol 3Radiotherapy, Adjuvant 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Esophageal Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT05828381 2023-04-25

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Fujian Medical University Union Hospital

Phase 2 Unknown
33 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04460066 2022-05-04

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Lee's Pharmaceutical Limited

Phase 1/2 Unknown
70 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT05007145 2021-12-21

REVO

Fujian Cancer Hospital

Phase 2 Unknown
92 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04177875 2019-11-26

T+TP

Tongji Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡